ES2229804T3 - Etannolato de azitromicina, procedimiento para su fabricacion y composiciones farmaceuticas que lo contienen. - Google Patents
Etannolato de azitromicina, procedimiento para su fabricacion y composiciones farmaceuticas que lo contienen.Info
- Publication number
- ES2229804T3 ES2229804T3 ES99965069T ES99965069T ES2229804T3 ES 2229804 T3 ES2229804 T3 ES 2229804T3 ES 99965069 T ES99965069 T ES 99965069T ES 99965069 T ES99965069 T ES 99965069T ES 2229804 T3 ES2229804 T3 ES 2229804T3
- Authority
- ES
- Spain
- Prior art keywords
- approximately
- ethanolate
- azithromycin
- suspension
- water content
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229960004099 azithromycin Drugs 0.000 title claims abstract description 43
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 title claims abstract description 42
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 title claims abstract description 31
- 238000000034 method Methods 0.000 title claims description 20
- 238000004519 manufacturing process Methods 0.000 title claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- 239000000725 suspension Substances 0.000 claims description 11
- 238000002425 crystallisation Methods 0.000 claims description 8
- 230000008025 crystallization Effects 0.000 claims description 8
- 239000013078 crystal Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 150000004682 monohydrates Chemical class 0.000 description 4
- HQUPLSLYZHKKQT-WVVFQGGUSA-N (2r,3s,4r,5r,8r,10r,11r,12s,13s,14r)-11-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-13-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-o Chemical compound O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 HQUPLSLYZHKKQT-WVVFQGGUSA-N 0.000 description 3
- 229960003256 azithromycin monohydrate Drugs 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
- 229930006677 Erythromycin A Natural products 0.000 description 1
- 238000003109 Karl Fischer titration Methods 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- -1 azithromycin ethanolates Chemical class 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11029898P | 1998-11-30 | 1998-11-30 | |
| US110298P | 1998-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2229804T3 true ES2229804T3 (es) | 2005-04-16 |
Family
ID=22332273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES99965069T Expired - Lifetime ES2229804T3 (es) | 1998-11-30 | 1999-11-30 | Etannolato de azitromicina, procedimiento para su fabricacion y composiciones farmaceuticas que lo contienen. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6365574B2 (enExample) |
| EP (2) | EP1484062A1 (enExample) |
| JP (1) | JP2002531409A (enExample) |
| KR (1) | KR100603226B1 (enExample) |
| CN (2) | CN100339384C (enExample) |
| AP (1) | AP1709A (enExample) |
| AT (1) | ATE279200T1 (enExample) |
| AU (1) | AU768219B2 (enExample) |
| BG (1) | BG105547A (enExample) |
| CA (1) | CA2352562A1 (enExample) |
| CZ (1) | CZ20011886A3 (enExample) |
| DE (1) | DE69921192T2 (enExample) |
| DK (1) | DK1152765T3 (enExample) |
| ES (1) | ES2229804T3 (enExample) |
| HK (1) | HK1043725B (enExample) |
| HU (1) | HUP0104241A3 (enExample) |
| IL (1) | IL143376A0 (enExample) |
| LV (1) | LV12735B (enExample) |
| NZ (1) | NZ512496A (enExample) |
| PL (1) | PL197894B1 (enExample) |
| PT (1) | PT1152765E (enExample) |
| RO (1) | RO121408B1 (enExample) |
| RU (1) | RU2240124C2 (enExample) |
| SI (1) | SI20639A (enExample) |
| WO (1) | WO2000032203A1 (enExample) |
| ZA (1) | ZA200104312B (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20020231A2 (en) * | 2002-03-18 | 2003-12-31 | Pliva D D | ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A |
| TW546302B (en) * | 1998-05-08 | 2003-08-11 | Biochemie Sa | Improvements in macrolide production |
| US6245903B1 (en) | 1998-08-21 | 2001-06-12 | Apotex, Inc. | Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof |
| US6365574B2 (en) * | 1998-11-30 | 2002-04-02 | Teva Pharmaceutical Industries Ltd. | Ethanolate of azithromycin, process for manufacture, and pharmaceutical compositions thereof |
| HU229488B1 (hu) * | 2000-11-27 | 2014-01-28 | Sandoz Ag | Eljárás makrolid hidrátok elõállítására |
| UA76967C2 (uk) * | 2000-11-27 | 2006-10-16 | Сандоз Аг | Азитроміцин у формі моногідрату, фармацевтична композиція та спосіб його одержання |
| KR100431431B1 (ko) * | 2001-04-25 | 2004-05-14 | 한미약품 주식회사 | 아지트로마이신 수화물의 1,2-프로필렌글리콜 내포화합물,그의 제조방법 및 그의 약학적 조성물 |
| US6861413B2 (en) * | 2001-05-22 | 2005-03-01 | Pfizer Inc. | Stable non-dihydrate azithromycin oral suspensions |
| DE60209704T2 (de) * | 2001-05-22 | 2006-11-16 | Pfizer Products Inc., Groton | Neue kristallforme von azithromycin |
| EP1652851A1 (en) | 2001-05-22 | 2006-05-03 | Pfizer Products Inc. | New crystal form of Azithromycin |
| WO2003032922A2 (en) * | 2001-10-18 | 2003-04-24 | Teva Pharmaceutical Industries Ltd. | Stabilized azithromycin compositions |
| EP1541134A3 (en) * | 2001-10-18 | 2007-06-06 | Teva Pharmaceutical Industries Limited | Stabilized azithromycin compositions |
| US20080149521A9 (en) * | 2001-10-18 | 2008-06-26 | Michael Pesachovich | Methods of stabilizing azithromycin |
| NZ532707A (en) * | 2001-12-21 | 2006-07-28 | Pfizer Prod Inc | Directly compressible formulations of azithromycin |
| NZ532063A (en) * | 2001-12-21 | 2006-03-31 | Pfizer Prod Inc | Methods for wet granulating azithromycin |
| MXPA04007427A (es) * | 2002-02-01 | 2004-10-11 | Pfizer Prod Inc | Formulaciones de azitromicina granuladas por via seca. |
| HRP20020614A2 (en) | 2002-07-22 | 2004-06-30 | PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. | Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a |
| US20050013835A1 (en) * | 2003-07-15 | 2005-01-20 | Pfizer Inc. | Stable non-dihydrate azithromycin oral suspensions |
| US20050101547A1 (en) * | 2003-11-06 | 2005-05-12 | Sadatrezaei Mohsen | Stabilized azithromycin composition |
| WO2005053652A1 (en) | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride |
| JP2007513147A (ja) * | 2003-12-04 | 2007-05-24 | ファイザー・プロダクツ・インク | 押し出し機を使用して、好ましくはポロキサマーとグリセリドを含有する多粒子結晶性医薬組成物を製造するための噴霧凝結方法 |
| WO2005053651A1 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Multiparticulate compositions with improved stability |
| BRPI0417338A (pt) * | 2003-12-04 | 2007-04-17 | Pfizer Prod Inc | formas de dosagem de azitromicina multiparticulada por processos a base de lìquido |
| US6984403B2 (en) * | 2003-12-04 | 2006-01-10 | Pfizer Inc. | Azithromycin dosage forms with reduced side effects |
| RU2331410C2 (ru) * | 2003-12-04 | 2008-08-20 | Пфайзер Продактс Инк. | Способ получения фармацевтических мультичастиц |
| WO2005053639A2 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Controlled release multiparticulates formed with dissolution enhancers |
| US7943585B2 (en) | 2003-12-22 | 2011-05-17 | Sandoz, Inc. | Extended release antibiotic composition |
| US20060116336A1 (en) * | 2004-03-17 | 2006-06-01 | American Pharmaceutical Partners, Inc. | Lyophilized azithromycin formulation |
| US7468428B2 (en) * | 2004-03-17 | 2008-12-23 | App Pharmaceuticals, Llc | Lyophilized azithromycin formulation |
| US7683162B2 (en) * | 2004-08-30 | 2010-03-23 | Taro Pharmaceutical Industries Limited | Process of preparing a crystalline azithromycin monohydrate |
| CA2591744A1 (en) * | 2004-12-21 | 2006-06-29 | Pfizer Products Inc. | Stable non-dihydrate azithromycin oral suspensions |
| US20060198895A1 (en) * | 2005-03-07 | 2006-09-07 | Kotliar Eleonora M | Azithromycin powder for oral suspension compositions |
| US20090318375A1 (en) * | 2005-06-08 | 2009-12-24 | Hanmi Pharm Co., Ltd | Crystalline Azithromycin L-Malate Monohydrate and Pharmaceutical Composition Containing Same |
| CN102413826A (zh) | 2009-03-13 | 2012-04-11 | 达·沃尔泰拉公司 | 用于消除革兰氏阴性菌的组合物和方法 |
| EP3366326A1 (en) * | 2009-04-17 | 2018-08-29 | Micell Technologies, Inc. | Stents having controlled elution |
| WO2013088274A1 (en) | 2011-12-14 | 2013-06-20 | Wockhardt Limited | Anhydrous amorphous azithromycin composition free of azithromycin dihydrate |
| CN103983730B (zh) * | 2014-06-11 | 2015-09-30 | 北京市药品检验所 | 阿奇霉素或其制剂中的杂质检查方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU43006B (en) | 1981-03-06 | 1989-02-28 | Pliva Pharm & Chem Works | Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof |
| US4474768A (en) | 1982-07-19 | 1984-10-02 | Pfizer Inc. | N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor |
| MX12213A (es) * | 1987-07-09 | 1993-05-01 | Pfizer | Metodo de preparacion de dihidrato de azitromicina cristalino |
| WO1989002271A1 (en) * | 1987-09-10 | 1989-03-23 | Pfizer | Azithromycin and derivatives as antiprotozoal agents |
| CN1093370A (zh) * | 1993-12-10 | 1994-10-12 | 北京市集才药物研究所 | 一种新的阿齐红霉素结晶及其制备方法 |
| CN1161971A (zh) * | 1997-01-03 | 1997-10-15 | 石家庄制药集团有限公司 | 一种阿齐霉素结晶及其制备方法 |
| US6245903B1 (en) * | 1998-08-21 | 2001-06-12 | Apotex, Inc. | Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof |
| US6365574B2 (en) * | 1998-11-30 | 2002-04-02 | Teva Pharmaceutical Industries Ltd. | Ethanolate of azithromycin, process for manufacture, and pharmaceutical compositions thereof |
| KR100491183B1 (ko) * | 2001-03-21 | 2005-05-25 | 한미약품 주식회사 | 아지트로마이신의 제조방법 및 이 방법에 사용되는9-데옥소-9에이-아자-9에이-호모에리트로마이신 에이의결정성 수화물 |
| DE60209704T2 (de) * | 2001-05-22 | 2006-11-16 | Pfizer Products Inc., Groton | Neue kristallforme von azithromycin |
-
1999
- 1999-11-30 US US09/451,738 patent/US6365574B2/en not_active Expired - Lifetime
- 1999-11-30 CZ CZ20011886A patent/CZ20011886A3/cs unknown
- 1999-11-30 PL PL347971A patent/PL197894B1/pl not_active IP Right Cessation
- 1999-11-30 KR KR1020017006669A patent/KR100603226B1/ko not_active Expired - Fee Related
- 1999-11-30 DK DK99965069T patent/DK1152765T3/da active
- 1999-11-30 CN CNB2005100785525A patent/CN100339384C/zh not_active Expired - Fee Related
- 1999-11-30 SI SI9920086A patent/SI20639A/sl not_active IP Right Cessation
- 1999-11-30 CN CNB998158542A patent/CN1273142C/zh not_active Expired - Fee Related
- 1999-11-30 RO ROA200100573A patent/RO121408B1/ro unknown
- 1999-11-30 WO PCT/US1999/028368 patent/WO2000032203A1/en not_active Ceased
- 1999-11-30 RU RU2001118035/15A patent/RU2240124C2/ru not_active IP Right Cessation
- 1999-11-30 AP APAP/P/2001/002183A patent/AP1709A/en active
- 1999-11-30 PT PT99965069T patent/PT1152765E/pt unknown
- 1999-11-30 EP EP04014455A patent/EP1484062A1/en not_active Withdrawn
- 1999-11-30 HU HU0104241A patent/HUP0104241A3/hu unknown
- 1999-11-30 HK HK02102775.5A patent/HK1043725B/en not_active IP Right Cessation
- 1999-11-30 CA CA002352562A patent/CA2352562A1/en not_active Abandoned
- 1999-11-30 AT AT99965069T patent/ATE279200T1/de not_active IP Right Cessation
- 1999-11-30 DE DE69921192T patent/DE69921192T2/de not_active Expired - Fee Related
- 1999-11-30 NZ NZ512496A patent/NZ512496A/xx unknown
- 1999-11-30 IL IL14337699A patent/IL143376A0/xx unknown
- 1999-11-30 AU AU31065/00A patent/AU768219B2/en not_active Ceased
- 1999-11-30 JP JP2000584898A patent/JP2002531409A/ja active Pending
- 1999-11-30 EP EP99965069A patent/EP1152765B1/en not_active Expired - Lifetime
- 1999-11-30 ES ES99965069T patent/ES2229804T3/es not_active Expired - Lifetime
-
2001
- 2001-05-25 ZA ZA200104312A patent/ZA200104312B/en unknown
- 2001-05-29 BG BG105547A patent/BG105547A/xx unknown
- 2001-06-22 LV LVP-01-79A patent/LV12735B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100603226B1 (ko) | 아지스로마이신의 에탄올레이트, 이의 제조 방법 및 약학 조성물 | |
| ES2244491T3 (es) | Procedimiento para la preparacion de polimorfos de claritromicina y nuevo polimorfo iv. | |
| JPS62155240A (ja) | 治療用化合物 | |
| AU2009245817B2 (en) | Organic compounds | |
| SK403591A3 (en) | 2-ranitidine hydrochloride form, method of its preparation and pharmaceutical product with its contents | |
| JP2001506668A (ja) | ２−（プリン−９−イル）−テトラヒドロフラン−３，４−ジオール誘導体 | |
| WO2000032203A9 (en) | Ethanolate of azithromycin, process for manufacture, and pharmaceutical compositions thereof | |
| JP2003530321A (ja) | Ｎ−［４−［２−（２−アミノ−４，７−ジヒドロ−４−オキソ−３Ｈ−ピロロ［２，３−ｄ］ピリミジン−５−イル）エチル］ベンゾイル］−Ｌ−グルタミン酸の新規結晶形およびその製造方法 | |
| JPH01308282A (ja) | ジデオキシジデヒドロ炭素環式ヌクレオシド | |
| KR20020082682A (ko) | 아지트로마이신 수화물의 1,2-프로필렌글리콜 내포화합물,그의 제조방법 및 그의 약학적 조성물 | |
| CN100364994C (zh) | 培美曲塞二钠的一种新晶型及其制备方法 | |
| WO2008037011A1 (en) | Polycyclic agents for the treatment of respiratory syncytial virus infections | |
| KR100679904B1 (ko) | 피리미딘 뉴클레오시드 유도체의 결정 | |
| ES2331733T3 (es) | Derivados de 9-desoxo-9a-aza-9a-metil-9a-homoeritromicina a. | |
| JP4000397B2 (ja) | モルヒネ−６−グルクロニドの新しい結晶形熊 | |
| JP6883593B2 (ja) | ９−アミノメチル基置換のテトラサイクリン系化合物の結晶型及びその製造方法 | |
| JP2011518799A (ja) | ２’−ｏ，３’−ｎ−橋かけマクロライド | |
| EP3929178B1 (en) | CRYSTALLINE FORM OF A VALNEMULIN HYDROCHLORIDE HYDRATE, ITS PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITION CONTAINING THE CRYSTALLINE FORM | |
| CA2999009C (en) | Crystal form of 4-((1-methylpyrrol-2-yl)-carbonyl)-n-(4-(4-morpholin-1-yl-carbonylpiperidin-1-yl)-phenyl)-1-piperazinecarboxamide monohydrate | |
| CN117343072B (zh) | 一种1-取代肉桂酰基-2-氧代石蒜碱类化合物及其制备方法和应用 | |
| WO2017015784A1 (zh) | 奥比特嗪-富马酸盐、水合物、晶型及其制备方法 | |
| CN104119295B (zh) | 吩噻嗪类一氧化氮供体、其制备方法和用途 | |
| US20240239832A1 (en) | A process for the preparation of n4-hydroxycytidine and its derivatives | |
| JPH04198185A (ja) | イソチアゾロ〔５，４―ｂ〕ピリジン誘導体 | |
| CA3241167A1 (en) | Phenylethylidenehydrazine dimers and methods of using same |